Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65

NCT02341495 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Study was terminated early due to low patient accrual.

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Deferasirox
DRUG: Cholecalciferol
DRUG: Azacitidine

Sponsor

Elizabeth Henry